Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics has disclosed a change in director Miles Prince’s interests, confirming the issue of 16,667,000 unlisted options to him following shareholder approval at the company’s 25 November 2025 Annual General Meeting. The grant, made for nil cash consideration and without any disposal of existing securities, increases Prince’s direct exposure to the company’s equity and further aligns his incentives with shareholders, signalling continued confidence in Chimeric’s strategic direction in the competitive oncology biotech space.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited (ASX: CHM) is a biotechnology company focused on developing cell-based cancer therapies, with its activities centred on innovative treatments in the oncology sector for global healthcare markets.
Technical Sentiment Signal: Sell
Current Market Cap: A$12.75M
Learn more about CHM stock on TipRanks’ Stock Analysis page.